Our Chief Scientific Officer, Xiaokui Zhang, PhD, was profiled in the Insights Care article titled, “Xiaokui Zhang: Nurturing Healthcare Through Innovative Leadership.”
The article can be found here: https://insightscare.com/xiaokui-zhang-nurturing-healthcare-through-innovative-leadership/
Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.
Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.
10835 Road to the Cure
Ste. 100
San Diego, CA 92121
© 2024 Aspen Neuroscience - All Rights Reserved